AUG 18, 2016 6:20 AM PDT

Pancreatic Cancer: A Tale of Coercion and Thievery Emerges

WRITTEN BY: Xuan Pham

Faced with low nutrients and starvation, pancreatic cancer doesn’t back down. In fact, scientists have found that they can outsmart their environment and coerce nearby cells to feed them the essential fuels. The study highlights the complexity of pancreatic cancer biology and how we desperately need to stay ahead of this aggressive cancer type.
 

Image credit: Pixabay.com
 

Pancreatic cancer is notorious for its lethality. Only about 25 percent of patients survive past the one-year mark from diagnosis. A key contributor to the cancer’s aggressiveness is its ability to thrive in seemingly nutrient-poor environments. Where does the cancer get its fuel from when oxygen and blood sugar is scarce?
 
As it turns out, when the going gets rough, pancreatic cancer cells scavenge for nutrients by forcing other cells to feed it. In particular, the cancer cells exploit nearby stellate cells, which normally secrete metabolites in the pancreas for structural support. Pancreatic cancer cells can signal stellate cells to surge their metabolite production, leading to a 20 to 40 percent increase in the cancer cells’ metabolic output.
 
As if coercing stellates to make more essential metabolites weren’t enough, pancreatic cancer cells go a step further. They can cause the breakdown of cell parts in stellates – a process known as autophagy. Autophagy usually involves the breakdown of damaged organelles into basic building blocks (amino acids) that the cell can then recycle. In pancreatic cancer, the autophagy is selfishly spurred on because the cancer uses the amino acid parts for its fuel.

"Our study offers more proof that pancreatic cancers not only use fuel differently, but also scavenge for it far more effectively than many cancer types," said Alec Kimmelman, chair of the Department of Radiation Oncology in the Laura and Isaac Perlmutter Cancer Center at NYU Langone, and senior study author.
 
Pancreatic cancer is impressively cunning, and also very choosy, too. The amino acid that’s favored by the cancer is alanine. Kimmelman found that the cancer feeds the stolen amino acid into its mitochondria, where they are used in the Krebs cycle to generate energy. Using alanine also diverts more precious nutrients, like glucose, to other vital tasks, like making nucleotides.
 
"This work establishes the existence of a new kind of crosstalk between tumors and stellate cells," says Kimmelman. "Knowing this may help the field to design drugs that interfere with the astonishing metabolic flexibility that makes these cancers unique."
 


Additional source: NYU Langone press release

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 05, 2020
Immunology
Awakening Ancient DNA to Kill Cancer
NOV 05, 2020
Awakening Ancient DNA to Kill Cancer
In a recent study published in Nature, scientists from the University of Toronto described the discovery of ancient DNA ...
NOV 15, 2020
Genetics & Genomics
Novel Cancer-Driving Genes are Discovered
NOV 15, 2020
Novel Cancer-Driving Genes are Discovered
Cells have to be able to divide so new ones can replenish cells that get worn out, dysfunctional, or that accumulate dam ...
NOV 23, 2020
Cancer
Women show higher survival rates than men post lung cancer surgery
NOV 23, 2020
Women show higher survival rates than men post lung cancer surgery
New research published in the journal Chest shows that women fare better than men following lung cancer surgery. Th ...
DEC 16, 2020
Cancer
More young adults are being diagnosed with esophageal adenocarcinoma
DEC 16, 2020
More young adults are being diagnosed with esophageal adenocarcinoma
New research published in a journal of the American Association for Cancer Research, Cancer Epidemiology, Biomarkers &am ...
JAN 04, 2021
Cell & Molecular Biology
Good Results From Trial of CAR T Cell Therapy for Non-Hodgkin Lymphoma
JAN 04, 2021
Good Results From Trial of CAR T Cell Therapy for Non-Hodgkin Lymphoma
Researchers have reported positive results from a phase 2 clinical trial of a CAR T cell therapy called axicabtagene cil ...
DEC 31, 2020
Cancer
Does inflammation make ADT symptoms worse?
DEC 31, 2020
Does inflammation make ADT symptoms worse?
A new study published in the journal Cancer considers the impact of inflammation on prostate cancer patients underg ...
Loading Comments...